QGEN vs. VRTX: Qiagen vs. Vertex Pharmaceuticals Stock Comparison

Company Profile

Qiagen (QGEN) and Vertex Pharmaceuticals (VRTX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but QGEN is classified in Life Sciences Tools & Services while VRTX is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Qiagen (QGEN) at 10.81% and Vertex Pharmaceuticals (VRTX) at 20.80% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Qiagen (QGEN) at 18.20% and Vertex Pharmaceuticals (VRTX) at 30.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Qiagen (QGEN) at 27.75% and Vertex Pharmaceuticals (VRTX) at 35.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Qiagen (QGEN) at 5.65% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Qiagen (QGEN) reports EPS growth of 409.76%, ranked against its industry; Vertex Pharmaceuticals (VRTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Vertex Pharmaceuticals (VRTX) at 2.34 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VRTX.

Both Qiagen (QGEN) at 0.47 and Vertex Pharmaceuticals (VRTX) at 0.31 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Vertex Pharmaceuticals (VRTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.

Vertex Pharmaceuticals (VRTX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Qiagen (QGEN) at 27.21 and Vertex Pharmaceuticals (VRTX) at 35.21 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Qiagen (QGEN) at 4.91 and Vertex Pharmaceuticals (VRTX) at 10.71 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Qiagen (QGEN) at 2.99 is valued about in line with its industry on P/B ratio, while Vertex Pharmaceuticals (VRTX) at 6.63 carries an above-peer premium to book — VRTX is pricier on assets.

Valuation Metrics